ImageneBio Q2 2026 net loss $10.2M ($0.63/sh); cash $136.2M funds into Q1 2028

ImageneBio, Inc.

Net loss of $10.2M ($0.63 loss per share) vs $10.7M ($4.46) in Q2 2025.
Cash, equivalents and marketable securities $136.2M as of June 30, 2026.
R&D expenses $6.7M (up from $5.7M); G&A expenses $5.1M (up from $1.7M) YoY.
Phase 2b ADAPTIVE trial for olevaprubart in atopic dermatitis on track; topline data expected Q4 2027.
Appointed Yanina Grant-Huerta as CFO and Matt Robbins as General Counsel in July 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.